164 related articles for article (PubMed ID: 11930011)
1. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.
Chan D; Gera L; Stewart J; Helfrich B; Verella-Garcia M; Johnson G; Baron A; Yang J; Puck T; Bunn P
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4608-13. PubMed ID: 11930011
[TBL] [Abstract][Full Text] [Related]
2. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
3. [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism.
MacKinnon AC; Armstrong RA; Waters CM; Cummings J; Smyth JF; Haslett C; Sethi T
Br J Cancer; 1999 Jun; 80(7):1026-34. PubMed ID: 10362111
[TBL] [Abstract][Full Text] [Related]
4. LC/MS characterization of impurities and degradation products of a potent antitumor peptidic dimer, CU201.
Wang J; Krishnamoorthi V; Wang E; Yang C; Baptista D; Wu X; Liu M; Gardner M; Elkins P; Hines J; Liu P
J Pharm Biomed Anal; 2010 Mar; 51(4):824-33. PubMed ID: 19897331
[TBL] [Abstract][Full Text] [Related]
5. Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines.
Bunn PA; Chan D; Stewart J; Gera L; Tolley R; Jewett P; Tagawa M; Alford C; Mochzuki T; Yanaihara N
Cancer Res; 1994 Jul; 54(13):3602-10. PubMed ID: 7516822
[TBL] [Abstract][Full Text] [Related]
6. Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment.
Shafer SH; Williams CL
Int J Oncol; 2003 Aug; 23(2):389-400. PubMed ID: 12851688
[TBL] [Abstract][Full Text] [Related]
7. Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth.
Beekman A; Helfrich B; Bunn PA; Heasley LE
Cancer Res; 1998 Mar; 58(5):910-3. PubMed ID: 9500449
[TBL] [Abstract][Full Text] [Related]
8. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro.
Woll PJ; Rozengurt E
Cancer Res; 1990 Jul; 50(13):3968-73. PubMed ID: 1693879
[TBL] [Abstract][Full Text] [Related]
9. Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium.
Chuang SM; Wang IC; Yang JL
Carcinogenesis; 2000 Jul; 21(7):1423-32. PubMed ID: 10874022
[TBL] [Abstract][Full Text] [Related]
10. [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) induces AP-1 transcription and sensitizes cells to chemotherapy.
MacKinnon AC; Waters C; Rahman I; Harani N; Rintoul R; Haslett C; Sethi T
Br J Cancer; 2000 Oct; 83(7):941-8. PubMed ID: 10970698
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells.
Tallett A; Chilvers ER; Hannah S; Dransfield I; Lawson MF; Haslett C; Sethi T
Cancer Res; 1996 Sep; 56(18):4255-63. PubMed ID: 8797601
[TBL] [Abstract][Full Text] [Related]
12. Bradykinin antagonists as anti-cancer agents.
Stewart JM
Curr Pharm Des; 2003; 9(25):2036-42. PubMed ID: 14529414
[TBL] [Abstract][Full Text] [Related]
13. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
14. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.
Yoshida S; Kawaguchi H; Sato S; Ueda R; Furukawa K
Jpn J Cancer Res; 2002 Jul; 93(7):816-24. PubMed ID: 12149148
[TBL] [Abstract][Full Text] [Related]
15. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors.
Morissette G; Houle S; Gera L; Stewart JM; Marceau F
Br J Pharmacol; 2007 Feb; 150(3):369-79. PubMed ID: 17179948
[TBL] [Abstract][Full Text] [Related]
16. In various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist.
Drube S; Liebmann C
Br J Pharmacol; 2000 Dec; 131(8):1553-60. PubMed ID: 11139431
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activates two stress-activated protein kinases, c-Jun N-terminal kinase and p38, in HepG2 cells.
Mitsui H; Maruyama T; Kimura S; Takuwa Y
Hepatology; 1998 May; 27(5):1362-7. PubMed ID: 9581692
[TBL] [Abstract][Full Text] [Related]
18. The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells.
Bost F; McKay R; Dean N; Mercola D
J Biol Chem; 1997 Dec; 272(52):33422-9. PubMed ID: 9407138
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer.
Keshamouni VG; Reddy RC; Arenberg DA; Joel B; Thannickal VJ; Kalemkerian GP; Standiford TJ
Oncogene; 2004 Jan; 23(1):100-8. PubMed ID: 14712215
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
